HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Utah Court Overturns Ephedra Ban For Low-Dose Products

This article was originally published in The Tan Sheet

Executive Summary

A Utah federal court has barred FDA from enforcing its ban on ephedra products containing 10 mg or less of ephedrine alkaloids per daily dose

You may also be interested in...



Will Nutraceutical Succeed In Asking Supreme Court To Review Ephedra Ban?

According to food and drug lawyer Marc Ullman, it is unlikely the Supreme Court will review the 10th Circuit Court of Appeals decision affirming FDA's ban of ephedra in dietary supplements

Ephedra appeal

Nutraceutical Corporation will file by Jan. 8 a petition seeking Supreme Court review of an August decision by the U.S. Court of Appeals for the 10 Circuit that upholds FDA's ban of ephedra-containing products, according to an announcement by law firm Emord & Associates Oct. 19. The 10 Circuit denied a petition by Attorney Jonathan Emord for en banc rehearing of the decision, the law firm adds. The petition was filed Sept. 28 (1"The Tan Sheet" Oct. 9, 2006, p. 3). The appellate court overturned an April 2005 ruling by District Court Judge Tena Campbell that barred FDA from enforcing its ephedra ban for products containing 10 mg or less (2"The Tan Sheet" April 18, 2005, p. 5). The Supreme Court is not expected to review the case because it is unlikely to find that the exceptional importance standard has been met or that the case represents a conflicting precedent at the circuit level, says Attorney Marc Ullman (Ullman, Shapiro & Ullman). However, if the Supreme Court does not hear the case, it will continue on remand before Judge Campbell on two remaining causes of action under the Administrative Procedure Act that have not yet been tried, Emord says...

Nutraceutical Files For Appellate Court Rehearing Of Ephedra Ban Suit

The appellate court decision that upheld FDA's 2004 ephedra ban overextends the agency's authority and blurs the line between food and drug regulation, attorneys for marketer Nutraceutical say in a request for rehearing

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS126441

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel